tbuckley/cabot-search huggingface dataset:
Oncologists’ perceptions of cost and cancer care in India: A comparison of private practice (PPOs) and non-private practice oncologists (NPPOs).
Authors: Manisha Bhattacharya, Erika Paige Hamilton, Yousuf Zafar
Journal: Journal of Clinical Oncology (2013)

e17562 Background: Cancer incidence is increasing in India, where most patients lack health insurance. Little is known about how out-of-pocket costs affect cancer treatment decision-making by Indian physicians and patients. Methods: We conducted a cross-sectional survey of PPOs and NPPOs in 6 Indian metropolitan areas. Oncologists were surveyed about cost of care and cost discussions with patients. Descriptive statistics and Fisher’s exact tests were used to describe differences in cost perceptions and discussions. Results: 59 oncologists were surveyed (61% response). 78% (n=46) were men. 59% (n=34) were PPOs, and 41% (n=25) were NPPOs. Oncologists routinely discussed cost with their patients (96%, n=57); PPOs and NPPOs were equally likely to do so (p=1.00). According to oncologists, patients seeing NPPOs or PPOs were equally likely to discuss costs before deciding on treatment (p=0.14). 55% (n=32/58) of oncologists discussed cost with patients before prescribing diagnostic tests, and 79% (n=46/58) discussed cost before making treatment decisions. PPOs were more likely than NPPOs to believe that costs may discourage patients from presenting for an initial cancer evaluation (88% vs. 44%; p=0.0009). However, 71% of NPPOs (vs 44% of PPOs; p=0.06) believed that, once diagnosed, more than half of their patients found costs to be a barrier to receiving standard care. Oncologists reported the most costly components of care for their patients to be: 1) chemotherapy; 2) radiotherapy and diagnostic imaging (tied); 4) surgery; 5) indirect costs from lost wages and inpatient admission (tied). When asked about how to reduce costs, oncologists identified: lowering chemotherapy prices (88%, n=52); judicious use/ lowering cost of diagnostics (36%, n=21); optimizing the referral process (22%, n=13). Insurance/subsidies were identified by 15% (n=8). Conclusions: Cost is routinely discussed by Indian patients and oncologists across care settings. Cost can be a deterrent to initial evaluation and a barrier to receiving standard care. Oncologists more commonly suggested reducing costs of diagnostics and therapeutics, rather than expanding insurance or changing referral practices.
Clinical and economic burden of community-onset multidrug-resistant infections requiring hospitalization
Authors: I. López-Montesinos, A. Domínguez-Guasch, S. Gómez-Zorrilla, X. Duran-Jordà, A. Siverio-Parès, M.M. Arenas-Miras, M.M. Montero, L. Sorli Redó, S. Grau, J.P. Horcajada
Journal: Journal of Infection (2020)
Long-Term Survivors in Non-Small Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations: Data from a Randomized Phase III Study Comparing GEFITINIB with Carboplatin Plus Paclitaxel (NEJ002)
Authors: Y. Minegishi, K. Kobayashi, M. Maemondo, A. Inoue, S. Sugawara, S. Oizumi, K. Hagiwara, T. Nukiwa, S. Morita, A. Gemma
Journal: Annals of Oncology (2012)
The Interim Analysis of Nutrition and Immune Recovery and Stress Response after Laparoscopy or Open Surgery with Fast Track or Conventional Treatment (FTMDT Trial) In Resectable Colorectal Cancer
Authors: K.F. Ding, D. Xu, J. Li, Y.M. Song, J.W. Wang, F.F. Sun, J.J. Zhou, J. Zhou, Y. Liu, S.Z. Zhang
Journal: Annals of Oncology (2012)
A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Authors: T.Y. Seiwert, J. Fayette, D. Cupissol, J.M. DelCampo, P.M. Clement, J.M. Tourani, M. Degardin, A.S. Blackman, J. Cong, F. Solca, E. Ehrnrooth, E.E.W. Cohen
Journal: Annals of Oncology (2012)
A Phase II Study of Dovitinib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure of Two or More Tyrosine Kinase Inhibitors
Authors: Y. Kang, M.H. Ryu, J.J. Lee, I. Park, J.H. Park, B. Ryoo
Journal: Annals of Oncology (2012)
Pooled Analysis of Non-Interventional Studies of Everolimus in Patients with Metastatic Renal Cell Carcinoma (MRCC) Refractory to Anti-VEGF Therapy
Authors: L. Bergmann, U. Kube, L. Albiges, J. Eymard, M. Schmidinger, A. Bamias, M. Ktiouet, G. Fischer, D. Xanthaki, G. Guderian
Journal: Annals of Oncology (2012)
Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Authors: Neel S. Bhatt, Ruta Brazauskas, Stephanie Bo-Subait, Rachel B. Salit, Karen Syrjala, Heather R. Tecca, Minoo Battiwalla, David K. Buchbinder, Betty K. Hamilton, Rachel Phelan, Bronwen E. Shaw
Journal: Blood (2019)
Successful Induction and Long-Term Follow-up after FLAG-MG Therapy: Chemotherapy Followed by Gemtuzumab Ozogamicin in Six Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Y. Hirayama, T. Terui, K. Koike, T. Kusakabe, T. Ishihara, K. Ishitani, S. Iyama, T. Sato, R. Takimoto, M. Kobune, J. Kato
Journal: Annals of Oncology (2012)
Evaluation of a Carboplatin (CBDCA) Dosing Method in Devic Chemotherapy
Authors: K. Ito, M. Okamoto, Y. Kakumae, Y. Ando, M. Ando, S. Kumazawa, A. Okamoto, Y. Inaguma, H. Ohta, S. Yamada, N. Emi
Journal: Annals of Oncology (2012)
Efficacy of Influenza Vaccine (FLUVAX) in Patients Undergoing Chemotherapy
Authors: R. Kumar, D. Gordon, C.S. Karapetis, B. Koczwara, G. Kichenadasse, D. Dua, H. Takhar, K. Jain, Y. Honda-Okubo, S. Sukumaran
Journal: Annals of Oncology (2012)
Survival Impact of HER2 Status in Patients with Gastric Cancer: a Multicenter Large-Scale Study in Japan
Authors: Y. Kurokawa, N. Matsuura, Y. Kimura, R. Kawabata, S. Adachi, J. Fujita, K. Nishikawa, S. Takiguchi, M. Mori, Y. Doki
Journal: Annals of Oncology (2012)
A role for early oral exposure to house dust mite allergens through breast milk in IgE-mediated food allergy susceptibility
Authors: Akila Rekima, Chrystelle Bonnart, Patricia Macchiaverni, Jessica Metcalfe, Meri K. Tulic, Nicolas Halloin, Samah Rekima, Jon Genuneit, Samantha Zanelli, Samara Medeiros, Debra J. Palmer, Susan Prescott, Valerie Verhasselt
Journal: Journal of Allergy and Clinical Immunology (2020)
Corrections to “Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors”
Authors: C. Serrano, J. Cortés, L. De Mattos-Arruda, M. Bellet, P. Gómez, C. Saura, J. Pérez, M. Vidal, E. Muñoz-Couselo, M.J. Carreras, G. Sánchez-Ollé, J. Tabernero, J. Baselga, S. Di Cosimo
Journal: Annals of Oncology (2019)
Nivolumab treatment of relapsed/refractory Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis in adults
Authors: Pengpeng Liu, Xiangyu Pan, Chong Chen, Ting Niu, Xiao Shuai, Jian Wang, Xuelan Chen, Jiazhuo Liu, Yong Guo, Liping Xie, Yu Wu, Yu Liu, Ting Liu
Journal: Blood (2020)
Sharing Patient Data Without Exploiting Patients
Authors: Matthew S. McCoy, Steven Joffe, Ezekiel J. Emanuel
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P-0202 Expression Profile of Mirnas in Stage III Colorectal Tumours: Overexpressed Mirnas As Potential Circulating Biomarkers
Authors: Anna Brunet, Carles Pericay, Irene Moya, Emma Dotor, Aleydis Pisa, Alex Casalots, Xavier Serra-Aracil, Carles Oliva Joan, Anna Ruiz, Eugeni Saigí
Journal: Annals of Oncology (2012)
An Athletic Coach–Delivered Middle School Gender Violence Prevention Program
Authors: Elizabeth Miller, Kelley A. Jones, Lisa Ripper, Taylor Paglisotti, Paul Mulbah, Kaleab Z. Abebe
Journal: JAMA Pediatrics (2020)

Adolescent relationship abuse (ARA) and sexual violence (SV) reported among adolescents point to the need for prevention among middle school-age youths.To test an athletic coach-delivered relationship abuse and sexual violence prevention program among middle school male athletes.An unblinded cluster randomized clinical trial from spring 2015 to fall 2017 at 41 middle schools (38 clusters). The study included 973 male middle school athletes (ages 11-14 years; grades 6-8; participation rate 50%) followed up for 1 year (retention 86%).Coaching Boys Into Men (CBIM) is a prevention program that trains athletic coaches to talk to male athletes about (1) respectful relationship behaviors, (2) promoting more gender-equitable attitudes, and (3) positive bystander intervention when harmful behaviors among peers are witnessed.The primary outcome was change in positive bystander behaviors (ie, intervening in peers' disrespectful or harmful behaviors); secondary outcomes were changes in recognition of what constitutes abusive behavior, intentions to intervene, gender-equitable attitudes, and reduction in recent ARA/SV perpetration (at end of sports season and 1-year follow up).Of the 973 participants, 530 were white (54.5%), 282 were black (29.0%), 14 were Hispanic (1.4%), and the remainder were multiracial, other race/ethnicity, or not reported. Positive bystander behaviors increased at end of sports season and at 1-year follow-up (relative risk, 1.51; 95% CI, 1.06-2.16 and 1.53; 95% CI, 1.10-2.12, respectively) as did recognition of abuse (mean risk difference, 0.14; 95% CI, 0.01-0.27 and 0.14; 95% CI, 0.00-0.28, respectively). At 1-year follow-up, among those who ever dated, athletes on teams receiving CBIM had lower odds of reporting recent ARA/SV perpetration (odds ratio, 0.24; 95% CI, 0.09-0.65). Gender attitudes and intentions to intervene did not differ between study arms. In exploratory intensity-adjusted and per protocol analyses, athletes on teams receiving CBIM were more likely to report positive bystander behaviors and to endorse equitable gender attitudes and less likely to report ARA and sexual harassment perpetration 1 year later.An athletic coach-delivered program for middle school male athletes is an effective strategy for reducing relationship abuse among younger adolescents.ClinicalTrials.gov Identifier: NCT02331238.
The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients.
Authors: Andre Rotmann
Journal: Journal of Clinical Oncology (2013)

e22006^ Background: Impaired glucose metabolism and elevated blood glucose levels have been linked with increased cancer risk and cancer mortality. Furthermore a diet with a high glycemic load and carbohydrate intake is positively associated with an increased cancer risk in a subgroup of breast cancer patients. New therapies have been established addressing new targets controlling glucose metabolism. Upregulation of glucose metabolism in cancer can be in vivo visualized by the imaging technique FDG-PET. Recently it has been shown that the detection of the biomarker transketolase-like-1 (TKTL1) in macrophages allows the non-invasive detection of upregulated glucose metabolism in cancer patients. The epitope detection in macrophages (EDIM) has been established as a new technology for a non-invasive biomarker based detection and characterization of tumors as well as early detection of recurrence and/or metastasis. The biomarker Apo10 is highly specifically expressed in tumor cells irrespective of the tumor entity. Apo10 and TKTL1 offers the possibility to detect abnormal cell proliferation and up-regulated glucose metabolism, indicating neoplasias and the degree of malignancy. This new technology could be used to identify patients that will benefit from existing and new approved therapies. Recently the mTOR inhibitor everolimus has been approved for a subgroup of advanced breast cancer. Metformin, a drug addressing glucose metabolism, has been shown to reduce the incidence of invasive breast cancer in postmenopausal women. Methods: We use the EDIM-tests for early detection, monitoring and in aftercare. Additional we use the test to monitor new therapies. The results where compared to clinical observations and laboratory data. Results: Up to now we have tested more than 100 women with breast cancer for a period up to 4 years. Our results show a good concordance between the EDIM-tests and the clinical observations. Conclusions: Our data from patients with breast cancer are promising results worth to be further validated. The combination of the biomarkers Apo10 and TKTL1 with EDIM-technology could be a useful tool to identify and monitor cancer patients and the use of new therapies.
IGHV-未変異およびIGHV-変異慢性リンパ球性白血病細胞はあらゆる生物学的機能を備えた活性化誘発性デアミナーゼタンパク質を産生 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: E M Patten Piers, C Chu Charles, Albesiano Emilia, N Damle Rajendra, Yan Xiao-Jie, Kim Dorothy, Zhang Lu, R Magli Amanda, Barrientos Jacqueline, E Kolitz Jonathan, L Allen Steven, R Rai Kanti, Roa Sergio, K Mongini Patricia, Maccarthy Thomas, D Scharff Matthew, Chiorazzi Nicholas
Journal: Blood (2012)
Oral Metronomic Cyclophosphamide in Patients with Metastatic Castration-Resistant Prostate Cancer Stratified by Prior Docetaxel Therapy
Authors: R. Barroso-Sousa, A.C.R. Chaves, L.G. Fonseca, G. De Castro, C. Dzik, P.M. Hoff
Journal: Annals of Oncology (2012)
Phase I Study of Ombrabulin, a Vascular Disrupting Agent (VDA), Administered Every 3 Weeks to Japanese Patients with Advanced Solid Tumors
Authors: T. Kurata, H. Murakami, Y. Fujisaka, H. Kiyota, H. Hayashi, K. Tanaka, K. Nakagawa, Y. Onozawa, J. Watanabe, N. Yamamoto, T. Aoyama
Journal: Annals of Oncology (2012)
The Tyrol Study SCLC Project: Retrospective Analysis of Clinical Features and Therapeutic Outcome in 484 Small Cell Lung Cancer Patients Diagnosed 1991 – 2011
Authors: M. Fiegl, A. Pircher, W. Sterlacci, H. Jamnig, T. Schmid, M. Nevinny, G. Pall, W. Oberaigner, G. Zangerl, W. Hilbe
Journal: Annals of Oncology (2012)
MOF-derived nano-popcorns synthesized by sonochemistry as efficient sensitizers for tumor microwave thermal therapy
Authors: Ting Li, Qiong Wu, Wei Wang, Zengzhen Chen, Longfei Tan, Jie Yu, Changhui Fu, Xiangling Ren, Ping Liang, Jun Ren, Limin Ma, Xianwei Meng
Journal: Biomaterials (2020)
Eleven Thymic Epithelial Tumors: Our Institution Experience
Authors: A. Mogi, T. Tanaka, Y. Nakashima, E. Sato, Y. Ikari, N. Kunami, H. Katsuya, M. Goto, M. Ishizu, K. Ishizuka, Y. Takamatsu, K. Tamura
Journal: Annals of Oncology (2012)
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
Authors: Philip A Philip, Jill Lacy, Fabienne Portales, Alberto Sobrero, Roberto Pazo-Cid, José L Manzano Mozo, Edward J Kim, Scot Dowden, Ahmed Zakari, Christophe Borg, Eric Terrebonne, Fernando Rivera, Javier Sastre, Venu Bathini, Daniel López-Trabada, Jamil Asselah, Muhammad Wasif Saif, Jack Shiansong Li, Teng Jin Ong, Thomas Nydam, Pascal Hammel
Journal: The Lancet. Gastroenterology & hepatology (2020)
Proteomic and Circulating Free DNA Analysis Outcome Predictors in the Galaxy Trialtm (NCT01348126): A Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIB/IV NSCLC
Authors: D. Fennell, E. Petricoin, J. Shaw, I. El Hariry, V. Vukovic, F. Teofilovici, V. Reichert, R. Rosell
Journal: Annals of Oncology (2012)
P-0232 Colorectal Cancer Screening by Human DNA Stool Quantification
Authors: Jacqueline de Lima, Yolanda Teixeira, Célia Pimenta, Aledson Felipe, Tiago da Silva, Vanessa Pazine, Mirella Soler, Ermelindo Libera Junior, Sarhan Saad, Nora Forones
Journal: Annals of Oncology (2012)
Cumulative Exposure to Bevacizumab (BV) After Disease Progression (PD) Correlates with Survival in Non-Small Cell Lung Cancer (NSCLC): A Time-Dependent Analysis of the Aries Observational Cohort Study
Authors: T.J. Lynch, M. Jahanzeb, D.R. Spigel, A. Wozniak, L. Leon, S. Fish, E.D. Flick, D. Dalal, M.P. Kosty
Journal: Annals of Oncology (2012)
A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
Authors: Sandra E. Juul, Bryan A. Comstock, Rajan Wadhawan, Dennis E. Mayock, Sherry E. Courtney, Tonya Robinson, Kaashif A. Ahmad, Ellen Bendel-Stenzel, Mariana Baserga, Edmund F. LaGamma, L. Corbin Downey, Raghavendra Rao, Nancy Fahim, Andrea Lampland, Ivan D. Frantz III, Janine Y. Khan, Michael Weiss, Maureen M. Gilmore, Robin K. Ohls, Nishant Srinivasan, Jorge E. Perez, Victor McKay, Phuong T. Vu, Jean Lowe, Karl Kuban, T. Michael O’Shea, Adam L. Hartman, Patrick J. Heagerty
Journal: New England Journal of Medicine (2020)

High-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the benefits and safety of this therapy in extremely preterm infants have not been established.
In vitro corrosion resistance of a Ta2O5 nanofilm on MAO coated magnesium alloy AZ31 by atomic layer deposition
Authors: Chang-Yang Li, Chi Yu, Rong-Chang Zeng, Bo-Cheng Zhang, Lan-Yue Cui, Jun Wan, Yang Xia
Journal: Bioactive Materials (2020)

Micro-arc oxidation (MAO) coating with outstanding adhesion strength to Mg alloys has attracted more and more attention. However, owing to the porous structure, aggressive ions easily invaded the MAO/substrate interface through the through pores, limiting long-term corrosion resistance. Therefore, a dense and biocompatible tantalum oxide (Ta
Corrections to “Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis”
Authors: J. Cortes, V. Calvo, N. Ramírez-Merino, J. O'Shaughnessy, A. Brufsky, N. Robert, M. Vidal, E. Muñoz, J. Perez, S. Dawood, C. Saura, S. Di Cosimo, A. González-Martín, M. Bellet, O.E. Silva, D. Miles, A. Llombart, J. Baselga
Journal: Annals of Oncology (2019)
Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM‐HF trial
Authors: Rosita Zakeri, John M. Morgan, Patrick Phillips, Sue Kitt, G. Andre Ng, Janet M. McComb, Simon Williams, David J. Wright, Jaswinder S. Gill, Alison Seed, Klaus K. Witte, Martin R. Cowie
Journal: European Journal of Heart Failure (2020)
Tyrosine Kinase Inhibitors without Radiation Therapy for Brain Metastases from Egfr-Mutant Adenocarcinoma of Lung
Authors: T. Iuchi, M. Shingyoji, T. Sakaida, S. Yokoi, M. Itakura, K. Kawasaki, Y. Hasegawa, H. Kageyama, T. Iizasa
Journal: Annals of Oncology (2012)
Abstract 150: AED Transportation System With Smartphone Application Cooperating With Dispatch Center
Authors: Takeyuki Kiguchi, Tomonari Shimamoto, Yosuke Homma, Chika Nishiyama, Takashi Kawamura, Taku Iwami
Journal: Circulation (2019)

Background: Although public access automated external defibrillators (AEDs) have been widely installed in Japan, defibrillation by public access AEDs was still rare. Methods: Study design: Case series. We developed an AED transportation system with smartphone application cooperating with dispatch center. When a cardiac arrest occurs and lay-person call the emergency service, the dispatcher share information of out-of-hospital cardiac arrest OHCA locations and near-by AEDs via the application with pre-registered volunteers near the victim. This application presents the shortest route to the OHCA scene via nearby AED, and the volunteers bring AED to the OHCA scene. The purpose of this study is to use this system in real settings and to make the task of the system clear. We conducted the experimental study in Owariasahi city, Aichi and Kashiwa city, Chiba. Research period were from January 2017 to March 2019 in Owariasahi city, and from December 2018 to March 2019 in Kashiwa city. We collected the number of registered volunteers, the timeline data of system activation, and the number of responses to occurrence of OHCA by registered volunteers during the study period. Results: In Owariasahi city, total of 304 volunteers were registered. 276 suspected OHCAs occurred, 179 cases were eligible excluding the hazardous cases in the scene, and of which 169 cases actually activated the system by the dispatcher. The average time from call to send notification was 3:11 (minutes and seconds) and from call to emergency medical service (EMS) arrival 6:37 (minutes and seconds). The registered volunteer took actions in 94/169 cases (55.6%), transported AEDs in 6 cases, and arrived on the scene in 10 cases. A registered volunteer arrived on the scene earlier than EMS personnel in one case. In Kashiwa city, total of 636 volunteers were registered, and the system was activated in 17 suspected OHCA cases. In one case, a volunteer arrived earlier than EMS and attempted resuscitation. Conclusions: This AED transportation system worked well and safe on the actual emergency scene. By increasing the number of registered volunteers, it is expected to increase the number of AED use.